Latest Articles

MWC collaboration solves elusive protein structure

MWC collaboration solves elusive protein structure

17 May 2016

A collaboration between chemists and biologists from the Maurice Wilkins Centre has enabled researchers to solve the structure of a potent antimicrobial protein with potential to tackle bacterial diseases in kiwifruit vines.

read more

Promising New Zealand compound selected as drug candidate for tuberculosis

17 September 2012

A New Zealand-designed compound that shows promise against treatment-resistance tuberculosis (TB) has been selected as a drug candidate by international non-profit drug developer the Global Alliance for TB Drug Development (TB Alliance).

read more

Local cancer drug approved for first clinical trial in United States and New Zealand

30 August 2012

The US Food and Drug Administration (FDA) has granted approval for PR610, an anticancer “stealth” drug invented in New Zealand, to move forward to human clinical trials through its approval of an Investigational New Drug (IND) Application for the drug.

read more

Second New Zealand anticancer “stealth” drug targeted for clinical development

4 August 2011

A second anticancer “stealth” drug designed by New Zealand scientists has been targeted for clinical development under a collaborative agreement between Proacta Incorporated (San Diego) and Yakult Honsha Co., Ltd. (Tokyo).

read more

New Zealand cancer drug to commence clinical trials

13 June 2011

A novel cancer drug designed by scientists from The University of Auckland and Maurice Wilkins Centre for Molecular Biodiscovery, and licensed to university spin-out company Pathway Therapeutics, Inc., has received approval from the US Food and Drug Administration to enter c...

read more

New Zealand-designed anti-tumour agent to enter clinical development

7 June 2011

A novel anti-tumour agent, CEN-209, created by New Zealand scientists will enter clinical development under two international agreements announced last week.

read more

New class of anticancer ‘stealth’ drug proceeds to clinical development

23 February 2011

The first of an exciting new class of anti-cancer drugs designed in New Zealand will proceed to clinical development in the United States, following the announcement today of a deal between Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo).

read more